Skip to main content

22-09-2020 | ESMO 2020 | Conference coverage | Video

OS results from SOLAR-1 trial of alpelisib reported

Fabrice André presents the overall survival data from the SOLAR-1 trial of alpelisib in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, and outlines the next steps for the further development of alpelisib and other PI3K inhibitors in this setting (4:34).

Read transcript